Half a Million Reasons to Hope
As of April 2026, 500,000+ people have been prescribed our long-acting injectable buprenorphine treatment for OUD.
Read moreAs of April 2026, 500,000+ people have been prescribed our long-acting injectable buprenorphine treatment for OUD.
Read moreIndivior attends the VCU Research to Recovery 2026 conference. Bridging science, lived experience, and frontline practice, Research to Recovery brought together the people who make recovery happen every day: peer recovery specialists, community clinicians, family advocates, harm reductionists, and individuals in long-term recovery.
Read moreIndivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder (OUD).
Read more